Why is Merck stock rallying today?

Merck (MRK) stock rose 2.1% in pre-market trading after reporting Q3 adjusted EPS of $2.49 (beating estimates) and revenue of $18.1B (exceeding consensus). The company raised its full-year revenue and earnings guidance. Keytruda sales grew 6% YoY to $8.6B, and WINREVAIR sales surged 93% YoY to $694M. Analysts increased price targets, with Jefferies setting a $177 target. The rally occurred against a cautious broader market backdrop.

Original reporting
Published Oct 29, 2026, 11:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MRK
Bullish
high confidence
Mentioned
$MRK
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

The earnings beat and guidance lift provide a clear catalyst for short‑term buying, while analysts' higher price targets reinforce bullish sentiment.

02

Market read

Merck's earnings beat and raised outlook drive a pre‑market rally, offering a timely trade opportunity.

03

What to watch

Rising competition in oncology and potential regulatory scrutiny on new formulations could temper gains.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Merck's Q3 results were released before market open, showing EPS $2.49 vs $2.09 estimate and revenue $18.1B vs $17.3B estimate, with guidance raised to $66.8B revenue and $2.77‑$2.82 EPS.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck reported Q3 earnings beating estimates and raised full-year revenue and earnings guidance, driving a 2.1% pre‑market rally.

Expected impact

likely upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

Earnings beat, revenue beat, and raised guidance are fresh, material information for a large‑cap pharma stock.

Market effects

Boosts sentiment for the broader healthcare/pharma sector as earnings beat suggests demand resilience.

U.S. equities may see modest lift despite broader cautious backdrop from tech futures.

Limited to U.S. markets; no immediate global macro effect.

Counterpoint

Investors may worry about long‑term Keytruda patent cliff in 2028, potentially capping upside.

Key entities

  • Merck & Co.

    Pharmaceutical company reporting Q3 earnings.

  • JPMorgan

    Raised price target to $165.

  • Jefferies

    Maintained Buy rating, raised target to $177.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.